Post-earnings recap
Reported
Mon, May 5, 2025
EPS actual
$-0.90
EPS est.
$-0.08
EPS surprise
-1025.00%
1-day move
-3.10%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Castle Biosciences reported a significant loss per share, which contributed to a 3.1% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial health and future performance. Without additional context from management, uncertainty remains regarding the company's strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.90 | N/A | -1025.00% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.